Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice by Hao, Jing et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Gastroenterology
Open Access Research article
Gastroesophageal reflux leads to esophageal cancer in a surgical 
model with mice
Jing Hao1, Ba Liu1, Chung S Yang1 and Xiaoxin Chen*1,2
Address: 1Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, 
The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, NJ 08854, USA and 2Cancer Research Program, Julius L. Chambers 
Biomedical/Biotechnology Research Institute, North Carolina Central University, 700 George Street, Durham, NC 27707, USA
Email: Jing Hao - haoj2@mail.nih.gov; Ba Liu - annaliu@rci.rutgers.edu; Chung S Yang - csyang@rci.rutgers.edu; 
Xiaoxin Chen* - lchen@nccu.edu
* Corresponding author    
Abstract
Background: Esophago-gastroduodenal anastomosis with rats mimics the development of human
Barrett's esophagus and esophageal adenocarcinoma by introducing mixed reflux of gastric and
duodenal contents into the esophagus. However, use of this rat model for mechanistic and
chemopreventive studies is limited due to lack of genetically modified rat strains. Therefore, a
mouse model of esophageal adenocarcinoma is needed.
Methods: We performed reflux surgery on wild-type, p53A135V transgenic, and INK4a/Arf+/- mice
of A/J strain. Some mice were also treated with omeprazole (1,400 ppm in diet), iron (50 mg/kg/m,
i.p.), or gastrectomy plus iron. Mouse esophagi were harvested at 20, 40 or 80 weeks after surgery
for histopathological analysis.
Results: At week 20, we observed metaplasia in wild-type mice (5%, 1/20) and p53A135V mice (5.3%,
1/19). At week 40, metaplasia was found in wild-type mice (16.2%, 6/37), p53A135V mice (4.8%, 2/
42), and wild-type mice also receiving gastrectomy and iron (6.7%, 1/15). Esophageal squamous cell
carcinoma developed in INK4a/Arf+/- mice (7.1%, 1/14), and wild-type mice receiving gastrectomy
and iron (21.4%, 3/14). Among 13 wild-type mice which were given iron from week 40 to 80, twelve
(92.3%) developed squamous cell carcinoma at week 80. None of these mice developed esophageal
adenocarcinoma.
Conclusion:  Surgically induced gastroesophageal reflux produced esophageal squamous cell
carcinoma, but not esophageal adenocarcinoma, in mice. Dominant negative p53  mutation,
heterozygous loss of INK4a/Arf, antacid treatment, iron supplementation, or gastrectomy failed to
promote esophageal adenocarcinoma in these mice. Further studies are needed in order to
develop a mouse model of esophageal adenocarcinoma.
Background
Esophageal adenocarcinoma is a rising malignancy in
western world in the past 30 years, and now exceeds the
incidence of esophageal squamous cell carcinoma [1]. It is
generally recognized that gastroesophageal reflux disease
(GERD) and Barrett's esophagus are the major risk factors
of esophageal adenocarcinoma [2]. Barrett's esophagus is
a metaplastic lesion of esophageal squamous epithelium
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adapted to GERD. The risk of esophageal adenocarcinoma
in patients with Barrett's esophagus is around 0.5% per
year [3]. Even with extensive treatment, the 5-year survival
rate of esophageal adenocarcinoma is still around 20%
[4]. Therefore, it is important to better understand the
underlying mechanisms of this disease.
Both genetic and environmental factors may contribute to
the development of esophageal adenocarcinoma. Along
with the progression of metaplasia, dysplasia and adeno-
carcinoma, p53 gene mutation and protein accumulation
were frequently detected [5,6]. It has been reported that
p16INK4a was frequently silenced by promoter hypermeth-
ylation in esophageal adenocarcinoma [7,8]. p14Arf was
also silenced by hypermethylation in some cases, yet to a
less extent compared with p16INK4a [7]. Among the envi-
ronmental factors, long-term antacid therapy might pro-
mote esophageal adenocarcinoma by producing
hypergastrinemia and promoting bile acid-induced muta-
genesis in a neutral pH environment [9,10]. Gastrectomy
might contribute to the development of esophageal aden-
ocarcinoma by inducing GERD [11]. Iron supplementa-
tion promoted carcinogenesis through oxidative stress as
we have shown in the surgical models with rats [12].
Animal models are great tools for research on human dis-
eases. An ideal animal model should recapitulate the dis-
ease in humans in etiology, pathogenesis, and molecular
features. Currently, the most popular animal models of
esophageal adenocarcinoma are surgical models with rats
[12-15]. Several strains of rats, e.g., Sprague-Dawley,
F344, Wistar, have been used to generate esophageal ade-
nocarcinoma [14,16,17]. Various surgical procedures,
such as esophagojejunostomy, esophagoduodenal anas-
tomosis, and esophagogastroduodenal anastomosis, have
been reported by us and others [12,14,15]. Both carcino-
genesis and chemoprevention studies using rat models
lead us to better understanding of esophageal adenocarci-
noma and possible preventive strategies [18-23]. How-
ever, the use of rat models in mechanistic studies has been
limited due to lack of genetically modified rat strains.
Mouse esophagus is very similar to rat esophagus in his-
tology. Several mouse models of esophageal adenocarci-
noma have been reported. Duncan et al. reported an E1A/
E1B transgenic mouse model [24]. The advantage of this
model was that mice developed adenocarcinoma at the
squamocolumnar junction without surgery or carcinogen
treatment. However, these mice can not be bred to keep a
stable line. Fein et al. reported a p53  knockout mouse
model with gastrectomy and esophagojejunostomy [25].
Out of twelve p53  knockout mice, 4 survived after 24
weeks of observation. Two of them had esophageal aden-
ocarcinoma and another one had squamous cell carci-
noma. In our study using p53 knockout mice, 28 of 32
operated mice died within 20 weeks after surgery and
most within 8 weeks, due to spontaneous lymphomas or
sarcomas. All of the 4 mice that survived 20 weeks after
surgery developed visible tumors of esophageal adenocar-
cinoma (unpublished data). Therefore, due to the short
life span of p53 knockout mice, application of this model
is very limited. Another research group reported a mouse
model of esophageal adenocarcinoma induced with
esophagojejunostomy and a carcinogen, N-methyl-N-
benzyl nitrosamine. Both wild-type and p27  knockout
mice of Swiss-Webster strain developed esophageal aden-
ocarcinoma and squamous cell carcinoma, yet at a low
frequency. With p27 knockout, the incidence of esopha-
geal adenocarcinoma was as low as 23.3% [26,27].
In this study, we aimed to develop a mouse model of
esophageal adenocarcinoma with a well-established surgi-
cal procedure, which successfully induced esophageal
adenocarcinoma in rats [12]. p53A135V mice carrying a
dominant negative mutation of p53 gene, which have a
longer life span and compromised p53 function [28], were
used to enhance carcinogenesis. INK4a/Arf+/- mice were
also included to test the potential effect of down-regula-
tion of p16INK4a  and  p14Arf  genes on carcinogenesis.
Besides, the potential roles of gastric acid and iron supple-
mentation in carcinogenesis were examined by combin-
ing surgery with acid suppression and/or iron
supplementation.
Methods
Animal breeding and maintenance
Wild-type A/J mice were obtained from the Jackson Labo-
ratory (Bar Harbor, ME) as breeders. Two genetically mod-
ified mouse strains were obtained from Dr. Ming You's
group at Washington University School of Medicine: [1]
A/J mice carrying three copies of an Ala-135-Val p53
mutant transgene [28]; [2] A/J mice with heterozygous
knockout of INK4a/Arf  [29]. PCR genotyping was per-
formed as described elsewhere [29].
We bred 151 male and 62 female wild-type mice, 36 male
and 42 female p53A135V transgenic mice, and 24 male and
5 female INK4a/Arf+/- mice for this study in our animal
facility. These mice were housed 10 per cage in plastic
cages with hardwood bedding and dust covers, in a HEPA-
filtered, environmentally controlled room (24 ± 1°C, 12/
12 h light/dark cycle). Animals were given lab chow
before surgery. Solid food was withdrawn for one day after
surgery. All mice were on AIN93M diet after surgery,
except that Group E received AIN93M diet supplemented
with 1,400 ppm omeprazole. All the diets were made by
Research Diets, Inc. (New Brunswick, NJ) once every
month and kept at 4°C until use.
Surgical procedures
Six- to eight-week-old A/J mice were administered anes-
thetics pre-mixed in normal saline (80 mg/kg ketamineBMC Gastroenterology 2009, 9:59 http://www.biomedcentral.com/1471-230X/9/59
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and 12 mg/kg xylazine, i.p.). Esophagogastroduodenal
anastomosis was performed through an upper midline
incision. Two 0.5 cm incisions were made on the esopha-
gus and the duodenum on the anti-mesenteric border,
and then were anastomosed together with accurate
mucosal to mucosal opposition. Total gastrectomy was
performed on some mice following the reflux procedure
(Figure 1). These surgical procedures were approved by
the Animal Care and Facilities Committee at Rutgers Uni-
versity (protocol no. 94-017).
After surgery, mice were divided into 6 groups: Group B
(reflux surgery, 49 male and 52 female wild-type mice);
Group C (reflux surgery, 36 male and 42 female p53A135V
transgenic mice); Group D (reflux surgery, 24 male and 5
female INK4a/Arf+/- mice); Group E (reflux surgery plus
omeprazole and iron, 36 male wild-type mice); Group F
(reflux surgery plus iron, 30 male wild-type mice); and
Group G (reflux surgery plus gastrectomy and iron, 26
male wild-type mice). One group of wild-type mice (10
male and 10 female) were used as non-operated control
(Group A) (Table 1).
Iron dextran (50 mg Fe/kg/month; Henry Schein,
Melville, NY) was administered to mice of 4 groups
through i.p. injection. Group F and Group G received iron
supplementation starting from 2 weeks after surgery.
Group E received iron supplementation from 20 to 40
weeks after surgery and Group B from 40 to 80 weeks after
surgery.
All mice were euthanized by CO2. Esophagus was
removed, opened longitudinally, and fixed in 10% buff-
ered formalin for 24 h, and then transferred to 80% etha-
nol. The formalin-fixed esophagi were Swiss-rolled,
processed and embedded in paraffin. Serial sections (5
μm) were mounted onto glass slides and used for his-
topathological analysis.
Histopathological analysis and immunostaining
H&E staining was performed on slides (No. 1 and 30) for
diagnosis. Metaplasia was diagnosed when mucin-pro-
ducing cells were observed in the squamous epithelium of
mouse esophagus as confirmed by Alcian blue staining.
Squamous dysplasia was diagnosed when squamous epi-
thelial cells lost maturation and orientation with epithe-
lial disorganization. Esophageal squamous cell carcinoma
was diagnosed when squamous epithelial cells lost their
normal orientation, had a high nucleus-to-cytoplasm
ratio, and were heterochromatic, and dysplastic cells
broke basement membrane and invaded into lamina pro-
pria [30].
Tissue sections of wild-type mice (Group B) and p53A135V
transgenic mice (Group C) were stained for p53 protein in
the esophagus. Paraffin sections were dewaxed in xylene,
and rehydrated in a gradient of ethanol to distilled water.
After quenching endogenous peroxidase activity with 3%
hydrogen peroxide, tissue sections were incubated in nor-
mal horse serum to minimize non-specific binding. A pol-
yclonal p53 antibody (Cat# NCL-p53-CM5p, Vision
BioSystems Inc., Fremont, CA, 1:500) was applied at 4°C
overnight. Tissue sections were then incubated with sec-
ondary biotin conjugated antibody at room temperature
for 30 minutes. An avidin-biotin peroxidase complex
(Vector Laboratories, Burlingame, CA) was then applied,
and the staining was visualized with diaminobenzidine.
The sections were counterstained with Mayer's hematoxy-
lin.
Statistic analysis
We compared the incidence of cancer with the Fisher's
exact test.
Results
Most mice (85%, 255/300) survived the surgery. The rest
died of anesthesia, bleeding or unknown reasons during
the surgery. After surgery, mice lost about 3 to 5 g of body
weight, and then started to gain weight to a less extent
compared to the non-operated control mice (Figure 2). At
the end of the experiment, mice with reflux had slightly
lower body weight than the non-operated control. Fifty
three mice were excluded from this study. Among them,
16 were sacrificed due to sickness and 37 died before the
end of experiment (11 due to blockage of the gastrointes-
tinal tract, 4 due to infection subsequent to iron injection,
22 due to unknown reasons). Autopsy of these 22 mice
failed to find any noticeable abnormalities probably due
to decay of the bodies.
Normal mouse esophagus is covered by stratified kerati-
nized squamous epithelium consisting of several layers of
squamous epithelial cells (Figure 3A). Reflux surgery
induced hyperplasia of the squamous epithelium with
Surgical produces producing gastroesophageal reflux Figure 1
Surgical produces producing gastroesophageal reflux. 
(A) esophagogastroduodenal anastomosis; (B) esophagogas-
troduodenal anastomosis plus gastrectomy.
A BBMC Gastroenterology 2009, 9:59 http://www.biomedcentral.com/1471-230X/9/59
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infiltration of inflammatory cells in the epithelium and
submucosa of all the mice (Figure 3B). At week 40 and 80,
some mice developed squamous dysplasia and squamous
cell carcinoma (Figure 3C, D, G and 3H).
At 20 weeks after surgery, one esophageal sample with
metaplasia was found each in wild-type mice (Group B)
and p53A135V transgenic mice (Group C). Metaplasia was
confirmed by Alcian blue staining as scattered mucinous
cells in the middle of hyperplastic squamous cells (Figure
3E and 3F), as previously described in our rat model [31].
Mature goblet cells were not observed. The body weights
of omeprazole treatment group (Group E) were signifi-
cantly lower than the control group (data not shown).
At 40 weeks after surgery, we found 6, 2 and 1 esophageal
samples with metaplasia in wild-type mice (Group B),
p53A135V transgenic mice (Group C), and reflux plus gast-
rectomy with iron supplementation (Group G). Squa-
mous cell carcinoma was found in one INK4a/Arf+/-
mouse (Group C) and 3 wild-type mice treated with reflux
plus gastrectomy with iron supplementation (Group G).
The incidence of squamous cell carcinoma in mice treated
with reflux plus gastrectomy with iron supplementation
(Group G) was significantly higher than that of mice
treated with reflux alone (Group B) (p < 0.05).
Because we did not find any esophageal adenocarcinoma
at week 40, we decided to give iron supplementation to
the mice left in surgical control group (Group B). At 80
weeks after surgery, we found 12 mice with esophageal
squamous cell carcinoma in 13 wild-type mice. All squa-
mous cell carcinoma were located at the distal part of the
esophagus and invaded into the muscle layer (Figure 3G).
Under higher magnification, neoplastic cells appeared to
be originated from squamous epithelial cell, and were sur-
rounded by muscle fibers (Figure 3H). The only one
mouse without squamous cell carcinoma had mild squa-
mous dysplasia. Metaplasia was not observed in these
mice (Table 1).
Unexpectedly, none of the mice developed either esopha-
geal adenocarcinoma or typical intestinal metaplasia as
rats in our previous studies [31].
p53 expression in mouse esophagus
In order to examine the expression pattern of mutant p53
protein in the esophageal epithelium, we immunostained
p53 using a polyclonal p53 antibody. In the esophageal
epithelium of wild-type mice slight background staining
was observed. In contrast, strong nuclear staining was
Table 1: Development of metaplasia and squamous cell carcinoma in mouse esophagus due to gastroesophageal reflux
Week 20 Week 40 Week 80
Group Genotype Treatment Metaplasia Metaplasia Squamous cell carcinoma Squamous cell carcinoma
A Wild-type Non-operated control 0/10 0/10 0/10 -
B Wild-type Reflux surgery and
50 mg/kg/m Fe, i.p. (Wk 41 to 80)
1/20
(5%)
6/37
(16.2%)
0/37 12/13
(92.3%)
C p53A135V Reflux surgery 1/19
(5.3%)
2/42
(4.8%)
0/42 -
D INK4a/Arf+/- Reflux surgery 0/10 0/14 1/14
(7.1%)
-
E Wild-type Reflux surgery, omeprazole (1,400 ppm) 
and 50 mg/kg/m Fe, i.p. (Wk 21 to 40)
- 0/11 0/11
F Wild-type Reflux surgery and
50 mg/kg/m Fe, i.p. (Wk 2 to 40)
- 0/22 0/22 -
G Wild-type Reflux surgery, gastrectomy and
50 mg/kg/m Fe, i.p. (Wk 2 to 40)
-1 / 1 4
(6.7%)
3/14a
(21.4%)
-
a Compared with Group B (P < 0.05)
Average body weight of A/J mice after surgery Figure 2
Average body weight of A/J mice after surgery. Non-
operated control mice (Group A, --) had the highest body 
weight.
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observed in the basal cells of esophageal epithelium of the
p53A135V  transgenic mice, suggesting accumulation of
mutant p53 protein (Figure 4).
Discussion
This study was primarily aimed to develop a surgical
model of esophageal adenocarcinoma in mice. Reflux sur-
gery was performed on wild-type, p53A135V transgenic and
INK4a/Arf+/- mice of A/J background. In addition, omepra-
zole (1,400 ppm in diet), iron (50 mg/kg/m, i.p.), or gas-
trectomy plus iron, were given to some of these mice in
order to promote disease progression. Unexpectedly, we
only observed metaplasia as scattered mucinous cells, but
not typical intestinal metaplasia, in a small percentage of
mice. Moreover, squamous cell carcinoma, but not
esophageal adenocarcinoma, was induced.
Long-term gastroesophageal reflux in combination with
iron (Group B at week 80) produced a high incidence of
squamous cell carcinoma (92.3%, 12/13) in this study.
Although gastroesophageal reflux has been often associ-
ated with Barrett's esophagus and esophageal adenocarci-
noma, its association with squamous cell carcinoma has
also been well documented in the literature. It is known
that patients after total or partial gastrectomy had
increased risk of developing esophageal and laryngeal
squamous cell carcinoma [32-35]. Reflux either directly
induced or promoted esophageal squamous cell carci-
noma following carcinogen treatment in rat models
[36,37]. In a previous study using the esophagoduodenal
anastomosis procedure in rats, reflux increased the inci-
dence of esophageal squamous cell carcinoma induced by
2,6-dimethylnitrosomorpholine or methyl-n-amylnitro-
Histopathology of mouse esophagus after reflux surgery Figure 3
Histopathology of mouse esophagus after reflux surgery. (A) In the non-operated control group, the basal layer of the 
epithelium was smooth and the nuclei were in a single line. (B) The epithelium responded to surgery-induced reflux with hyper-
plasia. Layers of the squamous epithelium increased and papillae were enlarged. (C) After long-term reflux, the epithelial cells 
started to lose their polarity with condensed nuclei and increased mitosis. (D) Later on, the squamous epithelium lost its nor-
mal architecture. Dysplastic cells penetrated the basal membrane and invade into the stroma. (E) At 20 weeks after the sur-
gery, mucin-producing cells were observed in the parabasal layer of the squamous epithelium. (F) Alcian blue staining confirmed 
mucin secretion in these scattered mucinous cells. (G, H) At 80 weeks after surgery, squamous cell carcinoma was observed in 
the Swiss-rolled esophagus of a mouse in Group B. Panel H is magnification of part of Panel G.
AB CD
EF GH
H
p53 expression in the esophagi of wild-type and p53A135V  mice Figure 4
p53 expression in the esophagi of wild-type and 
p53A135V mice. Strong nuclear accumulation appeared in the 
esophageal epithelial cells of p53A135V mice, suggesting the 
mutant form of p53 protein.
50μ μ μ μm5 0 μ μ μ μm
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samine by 40% [14]. Nevertheless, it was interesting why
A/J mice were not susceptible to esophageal adenocarci-
noma after reflux surgery. It is possible that mouse
esophageal epithelium might respond to gastroesopha-
geal reflux differently from rat esophageal epithelium,
even though they are very similar in histology. Although
the exact underlying mechanism remains puzzling,
genetic factors may play a critical role.
Scattered mucinous cells were observed in mouse
esophagi after surgery, suggesting that induction of Bar-
rett's esophagus and esophageal adenocarcinoma in
mouse esophagus is still possible [31]. Our recent study
on the rat model and human Barrett's esophagus have
suggested squamous de-differentiation (i.e., loss of squa-
mous transcription factors, p63, sox2) and columnar dif-
ferentiation (i.e., gain of intestinal transcription factors,
Cdx1, Cdx2, GATA4, HNF1α) were two essential aspects
of intestinal metaplasia [38]. Since embryonic esophageal
epithelium of p63 knockout mice and hypomorphic sox2
mice showed metaplastic changes of morphology and
gene expression [39,40], we speculate that p63  or sox2
knockout mice may be more susceptible to Barrett's
esophagus and esophageal adenocarcinoma after surgery.
It is likely that proper combinations of genetic modifica-
tions and reflux surgery may be needed to induced Bar-
rett's esophagus and esophageal adenocarcinoma in
mouse esophagus.
Rodent models of esophageal adenocarcinoma have its
inherent limitations. Rodents have keratinized squamous
epithelium without submucosal glands in the esophagus,
whereas humans have non-keratinized squamous epithe-
lium with submucosal glands. When histological and
physiological resemblance to humans is considered, a
model with pigs may offer many advantages over rodent
models. As humans, pigs have non-keratinized stratified
squamous epithelium and submucosal glands in their
esophagi [41]. Pigs may develop GERD and stress ulcera-
tion of the esophagus [42]. Pigs are also well suited for
genetic modifications and surgery [43]. With endoscopy,
pig esophagus may provide plenty of tissue samples for
analysis. A pig model of Barrett's esophagus and esopha-
geal adenocarcinoma is currently under development in
our laboratory.
Conclusion
In conclusion, reflux surgery induced esophageal squa-
mous cell carcinoma, but not esophageal adenocarci-
noma, in wild-type, p53A135Vtransgenic and INK4a/Arf+/-
A/J mice. Further studies are needed in order to develop a
mouse model of esophageal adenocarcinoma.
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